Navigation Links
KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q
Date:11/13/2008

and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of predicting international regulatory approval, including timing; (11) the difficulty of predicting the pattern of inventory movements by the Company's customers; (12) the impact of competitive responses to the Company's sales, marketing and strategic efforts, including the introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries; (13) risks that the Company may not ultimately prevail in litigation, including challenges to our intellectual property rights by actual or potential competitors or to our ability to market generic products due to brand company patents and challenges to other companies' introduction or potential introduction of generic or competing products by third parties against products sold by the Company or its subsidiaries including without limitation the litigation and claims referred to in the above-referenced Form 12b-25 and in Note 16 of the Notes to the Consolidated Financial Statements in the Company's Form 10-Q for the quarter ended June 30, 2008; (14) the possibility that KV's current estimates of the financial effect of certain previously announced product recalls could prove to be incorrect; (15) whether any product recalls or product introductions results in litigation, agency action or material damages; (16) the possibility that the findings of the Audit Committee inquiry referenced in the Company's Form 10-Q for the quarter ended June 30, 2008, and/or finalizing and/or filing of the Company's financial statements for the first and second quarters of fiscal 2009, could have a material impact on the Company's previously reported or future financial results; (17) the possibility that the auction rate securities held by the Company may not return to liquidity or at their face value; and (18) the risks detailed from time-to-time in the Company's filings with the Securities a
'/>"/>
SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 2014 RBSEO Services, a well-established ... optimization service just at $99. RBSEO Services knows ... afford costly search engine optimization service. So, the ... affordablity and requirements into consideration. , The ... has not compromised with the service quality. The ...
(Date:11/27/2014)... CA, (PRWEB) November 26, 2014 ... browser-based presentation platform, focused on increasing audience engagement ... Britannic Technologies. Lintelus’ software platform includes a multitude ... and presenter in a collaborative, interactive multi-screen environment. ... and the presentation in real time on their ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Dr. Parsa ... themselves this holiday season! With Parsa Mohebi Hair Restoration’s ... off of their next FUE procedure, making it that ... FUE—which stands for “Follicular Unit Extraction”—is an advanced variety ... traditional “strip” Follicular Unit Transplantation (FUT). FUE, unlike FUT, ...
(Date:11/26/2014)... iFitDress.com, a well-known wedding dress manufacturer ... sweet 16 cocktail dresses . Included in the new ... Furthermore, all of these charming outfits are offered at ... company has promised that all of the sweet 16 ... is worth mentioning that all of them are set ...
(Date:11/26/2014)... By Alex Kramer ... -- People with rheumatoid arthritis may be more likely to ... to new research. The study found that those who ... remission. Being underweight also lowered the odds of remission. ... overweight population," said Dr. Susan Goodman, the study,s lead author ...
Breaking Medicine News(10 mins):Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Lintelus Showcases its Feature-Rich Presentation Technology Solution at Convergence Summit’s Annual Event in London 2Health News:FUE Special at Parsa Mohebi Hair Restoration This Holiday Season 2Health News:iFitDress.com: Trendy Sweet 16 Cocktail Dresses Unveiled 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 2Health News:Weight Could Influence Rheumatoid Arthritis Relief 3
... ... Association (AWWA) is urging students and job seekers to explore the water sector to discover ... rewarding. , ... May 4, 2010 -- As Drinking Water Week continues, the American Water Works Association ...
... VANCOUVER, BRITISH COLUMBIA Adolescents who don,t get enough ... play video games or text their friends. They also ... May 4 at the Pediatric Academic Societies (PAS) annual ... have shown a relationship between sleep and weight issues, ...
... ... use competitive intelligence data to develop actionable marketing strategies with the help of Evolve Creative ... ... marketing and design firm, now offers businesses in Hamilton a competitive intelligence analysis ...
... The Carrousel Yacht ... Florida. Renowned for its award-winning gourmet cuisine, the Carrousel Yacht is a boutique operation providing ... by Great Bay Yacht Charters and has been in the hospitality industry and yacht charter ... ...
... enzyme deficiency disorder, is one of many conditions with few ... today in Blood , the journal of the American ... II clinical trial of eliglustat tartrate, an oral therapy in ... genetic disorder affecting an estimated 1 in 50,000 to 1 ...
... a specific type of dopamine receptor gene respond ... without the genotype, according to new research from ... come from the first-ever placebo-controlled pharmacogenetic drug trial ... to evaluate variants of the DRD4 dopamine receptor ...
Cached Medicine News:Health News:During Drinking Water Week 2010, Water Sector Urges Students, Job Seekers to Work for Water 2Health News:Less sleep may add up to more pounds in adolescents 2Health News:Evolve Creative Media Offers Competitive Market Analysis to Assist Small Businesses in Hamilton 2Health News:Carrousel Yacht: Miami Private Yacht Charters With Style, Taste and Value 2Health News:Carrousel Yacht: Miami Private Yacht Charters With Style, Taste and Value 3Health News:Phase II study of an oral therapy for Gaucher disease yields positive results 2Health News:Research helps end guesswork in prescribing ADHD drug 2
(Date:11/26/2014)... and NEW YORK and ... As the leading distributor of market intelligence, MarketResearch.com is ... report by IQ4I Research and Consultancy focusing on the ... more about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Pharmaceutical Ingredients Global Market – Forecast to 2020 ...
(Date:11/26/2014)... 25, 2014  Medtronic,s roughly $43 billion ... widely discussed in the media for its US ... stronger leading player in one of the fastest ... healthcare market research firm said  the two companies ... diverse set of solutions spanning inpatient to home ...
(Date:11/26/2014)... Nov. 25, 2014  Breckenridge Pharmaceutical, Inc. announced ... ANDA agreement with Pii (Pharmaceutics International, Inc.) ( ... Breckenridge and Pii expect to develop and commercialize ... agreement, Pii will develop, manufacture and supply the ... products under its own label.  The drugs, comprised ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2
... CHICAGO, Sept. 10 Celsis In Vitro, Inc. (Celsis ... for the Northern District of Illinois in Chicago has ... and Life Technologies (the Defendants) due to their infringement ... Technologies of Carlsbad, California (Nasdaq: LIFE ) ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), ... pharmaceutical, biotechnology, and medical device industries, today announced that ... President and Chief Executive Officer and a director of ... search for a successor.  Dr. McKelvey will continue in ...
Cached Medicine Technology:Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 2Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 3ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 2ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer 3
... series SV stereomicroscopes are ... type. Thanks to their ... optimally adapt to the ... is an advantage which ...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
... Fluor 20x Water Dipping Objective is ... research where the objective is actually ... or brain slice. The objective provides ... with a numberical aperature of 0.50, ...
Medicine Products: